Evolent Health (EVH) Appoints Shawn Guertin to its Board

Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced that a new director nominee will stand for election to the Board of Directors at the annual meeting of stockholders scheduled to be held on June 5, 2025.

The Board has recommended Mr. Shawn Guertin for election. Mr. Guertin is an insurance and health care executive with nearly 40 years of actuarial, financial and management experience. Most recently, he served as Executive Vice President and Chief Financial Officer for CVS Health Corporation from May 2021 to October 2023.

Mr. Guertin's nomination follows a search process by the Board's Nominating and Governance Committee to refresh an independent director position.

"It is an honor to be nominated to the Board," said Mr. Guertin. "I believe that Evolent offers a differentiated product for payers seeking to deliver top-quality clinical outcomes and health care value to members living with complex health conditions. I'm excited for the opportunity to help drive shareholder value."

If elected, Mr. Guertin will be the sixth new independent director added to the Board in the past four years, reflecting the Board's emphasis on ensuring its corporate governance aligns with best-in-class practices.

"Shawn brings an impressive track record of driving growth and profitability in the health care industry, and we are excited about the opportunity to have him join the Board," said Evolent Board Chair Cheryl Scott.

Evolent Co-Founder and Chief Executive Officer Seth Blackley stated, "Shawn is a highly respected leader from some of America's best-known health care brands. We look forward to benefiting from his guidance and his passion for our mission."

Mr. Guertin would take the seat currently held by Diane Holder, who is not seeking re-election.

"I am incredibly grateful to Diane for her contributions to Evolent and the Board over the last 14 years. Diane has helped establish the company as a leader in value-based specialty care, and her legacy will always be linked to Evolent," said Mr. Blackley.

You May Also Be Interested In

• enCore Energy launches $250M at-the-market share offering
• BTQ Technologies signs MOU with Korean IT group Itcenglobal
• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance